HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ChromaDex TV Ads Increase Sales, Customer Base

Executive Summary

Tru Niagen sales made up more than 85% of first-quarter total, and TV ads launched in March drove a “dramatic increase” in customers, says CEO Robert Fried.

You may also be interested in...



ChromaDex Invests In Tru Niagen TV Ads As Study Results Spur Word-Of-Mouth Promotion

Firm emphasizes TV advertising spending and Walmart-related commercial launching in March in its earnings briefing. “We could go much broader than just sort of a male fitness sports-related cohort. We think it's a much broader-based market than that,” says CEO Robert Fried.

Phase II Of Parkinson’s Treatment Trial Starts For ChromaDex's Nicotinamide Riboside

ChromaDex completed its phase I clinical trial studying the effects of nicotinamide riboside on Parkinson’s Disease. Lead researcher Charalampos Tzoulis is “very excited about these results” and that the trial represents “a novel approach in experimental PD-therapy.”

Attention Shoppers And Investors: ChromaDex Makes Tru Niagen Available At Walmart

Tru Niagen products available at 3,800 US Walmart stores include a lower dose, 100 mg, that ChromaDex didn't previously market. Launch sparks heavy trading driving up firm's share price.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS152520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel